Pulse Biosciences Financial Statements
NASDAQ: PLSEHealth CareMedical/Dental InstrumentsUSD
53.81+3.83 (+7.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pulse Biosciences revenue and earnings
In fiscal 2025, Pulse Biosciences generated $350,000 in revenue, up 0.0% from fiscal 2024. Pulse Biosciences reported a net loss of $72.8 million, compared with a loss of $53.6 million a year earlier. Gross margin was -54.0% and operating margin -21982.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Pulse Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350.00K | 0 | 0 | 700.00K | 1.42M | 0 | — | — | — | — |
| Revenue growth (YoY) | — | — | -100.00% | -50.63% | — | — | — | — | — | — |
| Cost of Revenue | 539.00K | 0 | 0 | 11.94M | 1.97M | 0 | 600.00K | 600.00K | 800.00K | 500.00K |
| Gross Profit | -189.00K | 0 | 0 | -11.24M | -550.00K | 0 | — | — | — | — |
| Operating Expenses | 76.75M | 56.26M | 43.57M | 46.81M | 62.46M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M |
| Research & Development | 44.72M | 32.34M | 27.80M | 20.84M | 28.64M | 26.44M | 24.96M | 17.25M | 9.65M | 5.51M |
| Selling, General & Admin | 32.03M | 23.92M | — | — | — | — | — | — | — | — |
| Operating Income | -76.94M | -56.26M | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | -37.55M | -25.57M | -9.52M |
| Other Income (Expense) | 4.16M | 2.67M | 1.36M | -448.00K | -646.00K | 114.00K | 983.00K | — | — | — |
| Pretax Income | 72.80M | 53.60M | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | — | — |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Net Income | -72.78M | -53.59M | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | -25.57M | -9.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.08 | -0.92 | -0.85 | -1.72 | -2.28 | -2.14 | -2.26 | -2.20 | -1.73 | -0.86 |
| EPS (Diluted) | — | — | — | — | -2.28 | -2.14 | -2.26 | -2.20 | -1.73 | -0.86 |
| Shares Outstanding (Basic) | 67.40M | 58.40M | 49.74M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M |
| Shares Outstanding (Diluted) | — | — | — | — | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M |
| EBITDA | -76.53M | -55.74M | -43.03M | -57.37M | -62.53M | -49.53M | -47.46M | -36.90M | -25.23M | -9.42M |
| Gross Margin | -54.00% | — | — | -1606.29% | -38.79% | — | — | — | — | — |
| Operating Margin | -21982.57% | — | — | -8293.86% | -4443.86% | — | — | — | — | — |
| Net Margin | -20794.57% | — | — | -8357.86% | -4489.42% | — | — | — | — | — |
This table shows 10 annual periods of Pulse Biosciences's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PLSE's reporting calendar. What is a income statement?